A retrospective, observational study of impact of the timing of bamlanivimab administration on clinical outcomes in high-risk COVID-19 positive patients at a community hospital
Latest Information Update: 13 Sep 2021
At a glance
- Drugs Bamlanivimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 13 Sep 2021 New trial record
- 16 Aug 2021 Primary endpoint (hospitalization for COVID-related illness at 28 days (or treatment failure)) has not been met, according to Results published in the American Journal of Emergency Medicine.
- 16 Aug 2021 Results published in the American Journal of Emergency Medicine